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The pharmaceutical industry is responsible for proving
the efficacy, safety and quality of medicines, in other
words, for planning and implementing the necessary
studies. The US Food and Drug Administration (FDA)
authority participates actively in developing medicines
by means of giving advice, which is to some extent
binding on both parties.
FDA controls the development cycles of medicines,
and how the contents of their marketing authorisation
applications evolve. 
The need for product-specific advice has also been
recognised in the European Union. In terms of Article
51 of Council Regulation 2309/93/EEC, the functions of
The European Agency for the Evaluation of Medicinal
Products (EMEA) include giving scientific advice. In
practice, this function has been delegated to the Scientif-
ic Advice Review Group (SciARG) of the Committee for
Proprietary Medicinal Products (CPMP). Furthermore,
many national authorities, including the National
Agency for Medicines in Finland, give advice on request.
A major difference from the FDA procedure is that the
initiative in asking for advice is always taken by indus-
try, and the advice is not binding on either party.  In the
course of the advisory procedure, no standpoint is taken
on whether the reports and investigations would suffice
for marketing authorisation. Industry feedback on the
advice given by the National Agency for Medicines and
CPMP has been generally positive.
The pharmaceutical industry has the required pre-
clinical and clinical expertise for proving the efficacy,
safety and quality of medicines. Why, then, is the advice
given by the authorities needed? General and field of
therapy guidelines cannot comprehensively deal with all
issues arising during research and development. The
problems may concern pre-clinical research, the extent
of clinical research, the target group, efficacy variables,
end points, and the analysis of results. The companies
asking for advice must have a definite motivation for
the plan. The authority are asked to comment on the in-
terpretation of guidelines, the scientific details of re-
search plans, and to give advice on proposed changes of
research plans. The advice may only be ignored on justi-
fied grounds. 
From the pharmaceutical industry’s viewpoint, the
primary importance of the advisory service is to support
the marketing authorisation process of a medicine. For
the authority, the emphasis lies in protecting consumers’
interests. When the authority advises industry to change
its research plan, the underlying reason would be to
have the medicine examined in such a way that suffi-
cient information on its efficacy, safety and quality is
made available for the marketing authorisation decision
(positive or negative) to be based on. The need of scien-
tific advisory services to prove the efficacy and safety of
a new medicine in comparison to an existing, recognised
therapy alternative is clearly emphasised more in the Eu-
ropean Union than in the United States.
The questions of responsibility and liability of scien-
tific advisory services should be clear-cut. The advice
given should not be binding, and the activities should be
transparent. If the advice given were binding, it might
be construed as a precedent. Furthermore, if scientific
advice were binding in nature, the significance of the
advice could erode, as science and therapy practices de-
velop further. 
Regardless of advisory services, the pharmaceutical
industry will continue to carry responsibility for devel-
oping medicines and for producing sufficient evidence. 
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There has been an increase in sexual-
ly transmitted diseases in Finland in
recent years. The large increase in
the number of new cases of chlamy-
dia infection has caused particular
concern. In 2000, a total of 11,731
reports of chlamydia infection were
received by the register of infectious
diseases at the National Public
Health Institute (1). Most of the in-
fections occurred in the 20–24 year
old age group. New cases of gonor-
rhoea infection totalled 284, and
syphilis 204. About 9% of first-time
appointments at venereal disease
out-patient departments involve
condyloma and 4% involve genital
herpes (2).
Chlamydia
The majority of chlamydia infections
involve adolescents who are either
symptom-free or exhibit only minor
symptoms. The diagnostic methods
in use nowadays are more sensitive
and more acceptable to the patient
than before, and only a small
amount of first-void urine is required
for their implementation (3). Mod-
ern methods based on the identifica-
tion of nucleic acid also make target-
ed screenings for chlamydia possible,
and have been found to be cost-ef-
fective (4). The group especially at
risk of contracting chlamydia con-
sists of young adults who have sever-
al sexual partners, have previously
been infected with chlamydia and
use the contraceptive pill (5).
To treat uncomplicated chlamy-
dia a single dose of 1 g of azithro-
mycin is easily administered at the
appointment itself (6). Excellent
compliance is achieved with single
dose medication (7). Alternative
treatment and treatment in the com-
plicated cases especially should con-
sist of tetracycline 500 mg x 3, dox-
ycycline 100 mg x 2 or erythromycin
500 mg x 4 administered for a peri-
od of 7–10 days.
Giving guidance to the infection
carrier, and to those possibly infect-
ed, on how to make an appointment
and get treatment, is an essential
part of good treatment practice in all
venereal diseases and is, in fact, one
of the duties of the physician treating
the patient. The follow-up of infec-
tion, especially in the case of chlamy-
dia, should be intensified to allow
symptom-free carriers to be tracked
down more effectively. The post-
treatment control specimen of
chlamydia should be taken until
about 3–4 weeks after the treatment.
Gonorrhoea
Culture is still used in the diagnosis
of gonorrhoea; it also allows for the
assessment of sensitivity of gonococ-
cus to antimicrobial treatment. Gon-
orrhoeal infection can also be detect-
ed from a urine sample by a nucleic
acid detection method as in the case
of chlamydia.
For the treatment of uncompli-
cated gonorrhoea, the most com-
monly used treatment is ciproflox-
acin 500 mg x 1 (6), and 500 mg x 2
for the duration of one week for the
complicated disease. The problem
nowadays arises from strains of gon-
orrhoea originating mainly from the
Far East, which are often resistant to
quinolones (8). The alternative treat-
ment then is ceftriaxone 250 mg as a
single intramuscular dose. Ceftriax-
one is also recommended for the
treatment of gonorrhoea during
pregnancy (6). When using the cul-
ture method, the cure of gonorrhoea
infection is ascertained one week af-
ter the treatment, and when using
the nucleic acid detection method
this is carried out three weeks after
the treatment.
Syphilis
The number of new syphilis infec-
tions increased significantly in Fin-
land during the 1990s, mainly due to
the epidemic prevailing in Russia (9).
The detection of syphilis infection is
made difficult by its long incubation
period (3–4 weeks) and large varia-
tion in the range of symptoms, and
often also by its lack of symptoms.
Serology may still be negative when
the first symptoms appear (10). The
patients should be advised to seek
appointments at specialists to estab-
lish the stage of the disease, intro-
duce treatment and review the part-
ner situation.
The primary treatment of syphilis
is procaine penicillin 600,000 IU dai-
ly im. for 2 weeks at the primary
and secondary stage, and for 3
weeks at later stages (6). The alter-
native is im. ceftriaxone 1 g x 1. The
fall in the cardiolipin titre is moni-
tored after 3, 6 and 12 months. Peni-
cillin is also an effective treatment of
syphilis during pregnancy.
Genital herpes
The most common cause of genital
herpes is Herpes simplex virus type 2
(HSV-2), but nowadays about 20%
of the infections are caused by HSV-
1. Of the Finnish adult population
70% is HSV-1 positive and about
20% HSV-2 positive (11). Only a
proportion of those infected show
typical symptoms of herpes and
about half the infections are con-
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tracted from a symptom-free partner
or a partner unaware of his or her
infection (12).
Antiviral drugs will not kill the
virus but they can prevent its spread
(13). The aim of drug treatment is to
relieve the symptoms and prevent or
shorten the duration of attacks, and
thereby prevent others from becom-
ing infected. The three drugs aci-
clovir, famciclovir and valaciclovir
differ in dosage and price (6,14). The
treatment can be divided into treat-
ment of attacks and short and long-
term prophylaxis. The initial attack
may be an aggressive and long-term
general infection, and antivirals will
shorten the period of virus secretion
from 12 days to 9 days. Antiviral
treatment is given for 5–10 days. Re-
infections are usually of shorter du-
ration and associated with milder
symptoms. The need for treatment is
individual but to achieve the best
possible response treatment should
be initiated immediately at the onset
of the first symptoms. 
Short prophylactic treatment can
be used e.g. during holidays in which
case it is best to start the treatment
about a week before the journey.
Long-term prophylactic treatment
can be offered to patients with fre-
quently recurring herpes or herpes
associated with awkward symptoms.
In prophylactic treatment the dose
can be adjusted individually accord-
ing to the response, but usually aci-
clovir 400 mg x 2, famciclovir 250
mg x 2 or valaciclovir 500 mg x 1 is
adequate. The duration of treatment
varies from months to years. Symp-
tom-free virus secretion can be re-
duced by prophylactic medication
and thereby diminish the possibility
of infecting others (15).
Condyloma
Condyloma is caused by human pa-
pilloma viruses. Only a fraction of
those infected with a virus are found
to have microscopic warts in the
genital area (16). The diagnosis is
mainly based on the typical clinical
picture. The treatment is aimed at re-
moving the visible changes, but the
actual virus cannot be eradicated
from the body. The choice of treat-
ment is influenced by several factors,
e.g. the location, size and number of
the warts, the level of equipment of
the clinic, the patient’s opportunity
to attend appointments for treatment
and the price of treatment. There are
several alternative treatments for
condyloma, varying from topical
treatment to surgery, and the treat-
ment results are very variable. Re-
lapses of the condyloma are the
problem in all treatments (6). Many
patients go through all the alterna-
tive treatments during their therapy. 
The patient self can apply a
podophyllotoxin solution (0.5%) or
ointment (0.15%) on the warts on
three consecutive evenings a week or
with imiquimod ointment (5%) on
three days a week (6,17). A precon-
dition is that the patient should be
capable of distinguishing the changes
of warts from the normal skin and
mucous membrane. The out-patient
care can still continue with weekly
applications of podophyllin. Skin ir-
ritation may be a problem with these
topical treatments. Nor are they ap-
propriate for the treatment of condy-
lomata during pregnancy. 
Cryotherapy and laser treatments
are mainly given at out-patient clin-
ics. The problem with cryotherapy is
the pain it inflicts, and there may be
blisters developing in the treatment
area which clear within 1 to 2
weeks. Laser treatment is given un-
der local anaesthetic and the wound
areas usually heal within a couple of
weeks, but they do require follow-up
treatment.
The treatment of condyloma in
women involves regular PAP tests to
detect any cell changes in the uterine
cervix as early as possible. Patients
with condyloma are advised to use a
condom for 3–4 months after com-
pletion of treatment to prevent trans-
mission of infection because the risk
of relapse is at its highest during that
period.
Conclusion
A sexually transmitted infection is
found in 40,000 people in Finland
every year. All sexually transmitted
diseases may be symptom-free, or
exhibit only minor symptoms but
still be infectious. We have good di-
agnostic and effective treatment
available for sexually transmitted
diseases, but the number of infec-
tions detected annually is neverthe-
less on the increase. It is therefore
important to improve the guidance
given to infection carriers and those
exposed to infections by prompting
them to be present at appointments
for examination and treatment, and
aiming especially at controlling the
chlamydia epidemic in young adults.
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Antipsychotics are used for the
treatment of psychosis and of behav-
ioural symptoms comparable to psy-
chosis in severity. Other uses include
the treatment of symptoms of alco-
hol and drug abuse withdrawal and
states of confusion, restlessness and
aggressiveness among the elderly
and mentally retarded. The use of
antipsychotics as hypnotics or for
the treatment of anxiety or non-psy-
chotic affective syndrome should be
avoided (1).
Antipsychotics are divided into
two groups: the conventional an-
tipsychotics and the more recent
type of second-generation antipsy-
chotics. The earliest second-genera-
tion antipsychotics were introduced
on to the market in the 1970s (1,2).
The second-generation antipsy-
chotics may be considered as prima-
ry drugs in patients who have schiz-
ophrenic psychosis for the first time
(1). They cause fewer adverse effects
bearing on the quality of life of the
patient than do conventional an-
tipsychotics, and this has a positive
effect on the patient’s compliance
(1,2).
One of the oldest second-genera-
tion antipsychotics, clozapine, is in-
dicated for patients who have not
responded to, or do not tolerate,
other antipsychotics. Its use is asso-
ciated with a risk of agranulocytosis,
and therefore the blood count must
be regularly monitored during treat-
ment. Clozapine is considered the
best of the second-generation an-
tipsychotics, but newer second-gen-
eration antipsychotics have less bone
marrow toxicity (3). Risperidone
and olanzapine were introduced in
the mid 1990s (2)and the latest que-
tiapine was launched on the market
in 2000. 
The consumption of antipsy-
chotics has remained relatively
steady during the 1990s (Fig. 1). A
slight increase may be perceived
since 1998, but the total consump-
tion in 2000 (14.21 DDD/1,000 in-
habitants/day) is nevertheless slightly
lower than in 1990 (14.77
DDD/1,000 inhabitants/day). The
consumption of second-generation
antipsychotics has increased during
the entire 1990s at the same time as
the consumption of conventional an-
tipsychotics has dropped (Figs. 1
and 2). The increase in the con-
sumption of second-generation an-
tipsychotics is partly explained by
the introduction on to the market
olanzapine, risperidone and quetiap-
ine. The most significant decrease in
consumption (48%) among conven-
tional antipsychotics has occurred
with thioridazine, thioproperazine
and periciazine (Fig. 1).
The most frequently used sec-
ond-generation antipsychotics are
olanzapine, risperidone and clozap-
ine (Fig. 2). Three- or four-fold in-
crease in the consumption of olanza-
pine and risperidone has occurred
within the past few years, but the
consumption of clozapine has in-
creased moderately. The consump-
tion of sulpiride has dropped by
about 40% since the beginning of
the decade.
According to current therapeutic
practice, the aim is to treat patients
with psychosis in out-patient care
(4). The use of antipsychotics is con-
siderably higher in out-patient care
compared with treatment in institu-
tional care (Figs. 3 and 4). The num-
ber of available beds in psychiatric
specialist in-patient care has de-
creased steadily when patients have
been transferred from institutional
to out-patient care. The length of
periods in institutional care have al-
so been shortened (4).
The increase in the out-patient
consumption of second-generation
antipsychotics has been significantly
higher than that in in-patient institu-
tional care (Fig. 3). This is explained
by the introduction of therapies with
second-generation antipsychotics
(with the exception of clozapine).
The consumption of convention-
al antipsychotics has dropped, par-
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ticularly in institutional care (Fig. 4).
The decreased use of institutional
care may partly be due to the thera-
peutic practice which promotes out-
patient care and the use of more re-
cent second-generation antipsy-
chotics. The consumption of conven-
tional antipsychotics in out-patient
care has decreased only slightly be-
cause their use has probably been
continued in patients who have re-
sponded well to the drug they have
been using (1).
Among the aliphatic phenothiaz-
ines generally used in out-patient
care, the consumption of chlorpro-
mazine has decreased (Fig. 5), the
consumption of levopromazine has
varied (Fig. 6) and the consumption
of promazine has increased in the
1990s (Fig. 7). The use of promazine
in institutional care has remained
steady, but its consumption in out-
patient care has increased. Pro-
mazine and levopromazine have been
used as hypnotics in the non-psy-
chotic elderly (1, 5). This exposes
the patient to the extrapyramidal
and anticholinergic adverse effects of
these drugs, and therefore antipsy-
chotics should not be used as hyp-
notics without any other psychiatric
indications (1). However, based on
the increased out-patient consump-
tion it can be assumed that promaz-
ine and levomepromazine have possi-
bly been used even for other psy-
chotic symptoms more frequently
than other neuroleptic agents (Figs. 
6 and 7). In 1999, the most common
drug causing fatal intoxication was
levomepromazine and the third most
common drug was promazine (6).
According to Vuori (2000), the un-
derlying cause of a great proportion
of the fatal intoxications with pro-
mazine was alcohol, and it appears
that antipsychotics, especially pro-
mazine, are increasingly more com-
monly prescribed as sedatives and
sleep aids for alcohol abusers in lieu
of benzodiazepines. The absence of
small pack sizes and negligence in
following the instructions for dosage
can lead to fatal results in alcohol
abusers accustomed to less toxic
benzodiazepines (7). In view of in-
formation revealed by the consump-
tion data it may also be appropriate
to consider the availability of smaller
Fig. 2. Consumption of the second generation antipsychotics. 
Fig. 3. Consumption of the second generation antipsychotics.
Fig. 4. Consumption of the conventional neuropleptics. 
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pack sizes and to check the thera-
peutic indications.
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